| 1/46 | US=90 / Câncer Singh RP, Agarwal R,. SENCAR mouse-skin tumorigenesis model. In: Teicher BA. Tumor models in cancer research. New Jersey: Humana press, 2002. p. 359-80. |
| 2/46 | US=102 / Câncer Beuschlein F. Mouse models of adrenal tumorigenesis. In: Hammer GD, Else T. Adrenocortical carcinoma: basic science and clinical concepts. New York: Springer, 2011. p. 325-40. ISBN 978-0-387-77235-6. CAMUNDONGOS. EXPERIMENTOS; FATOR DE CRESCIMENTO; TRANSPLANTE; FENOTIPOS; EXPRESSAO TRANSGENICA |
| 3/46 | US=17 / Neurologia Farhadi HF, Rutka JT. Molecular markers and pathways in brain tumorigenesis. In: Bernstein M, Berger MS. Neuro-oncology: the essentials. 2ªed. New York: Thieme, 2008. p. 32-8. ISBN 978-3-13-116332-5. MARCADORES MOLECULARES; VIAS NA TUMORIGENESE CEREBRO; GLIOMAGENESE REGULACAO VIAS DE SINALIZACAO; DESREGULADO DE SINALIZACAO; DESENVOLVIMENTO EM MEDULOBLASTOMA; PATOGENESE MOLECULAR DOS MENINGIOMAS |
| 4/46 | US=60 / Biol/Mol Yang SY, Sales KM, Winslet MC. Apoptosis in colorectal tumorigenesis and chemotherapy. In: Chen GG, Lai PBS. Apoptosis in carcinogenesis and chemotherapy: apoptosis in cancer. New York: Springer, 2009. p. 75-109. ISBN 978-1-4020-9596-2. APOPTOSE; MORTE CELULAR PROGRAMADA; QUIMIOTERAPIA; CARCINOGENESE DO COLO UTERINO; CANCER COLORRETAL; PAPILOMAVIRUS HUMANO (HPV); CARCINOMA COLORRETAL. EPIDEMIOLOGIA; CARCINOMA COLORRETAL. ETIOLOGIA; CARCINOMA COLORRETAL. PATOLOGIA; CARCINOMA COLORRETAL. TRATAMENTO; TUMORIGENESE COLORRETAL; ADENOMA; MUTACAO GENICA |
| 5/46 | US=97 / Biol/Mol Atkinson MJ, Tapio S. Tumorigenesis. In: Molls M, Vaupel P, Nieder C, Anscher MS. The impact of tumor biology on cancer treatment and multidisciplinary strategies. Baltimore: Springer, 2009. p. 1-17. (Medical Radiology Radiation Oncology) ISBN 978-3-540-74385-9. TUMORIGENESE; CARCINOGENESE; HEREDITARIEDADE; ONCOGENES; GENES SUPRESSORES TUMORAIS; MICRORNAS; CANCER; ESTILO DE VIDA; FATORES AMBIENTAIS; FATORES OCUPACIONAIS; CELULAS-TRONCO; MICROAMBIENTE; CANCER INDUZIDO POR RADIACAO |
| 6/46 | US=101 / Câncer Kaminska B. Molecular characterization of inflammation-induced JNK/c-Jun signaling pathway in connection with tumorigenesis. In: Kozlov SV, editor. Inflammation and cancer: methods and protocols. volume 2, molecular analysis and pathways. New York: Humana Press, 2009. p. 249-64. (Methods in Molecular Biology, 512) ISBN 978-1-60327-529-3. TUMOR-HOSPEDEIRO INTERACOES; TGF-ß SINALIZACAO; INVASAO / CELULA MOTILIDADE; JNK / C-JUN VIA DE SINALIZACAO; AP-1 COMPLEXO; MUDANCA DE GEL |
| 7/46 | US=101 / Câncer Adach A, Ellert-Miklaszewska A, Kaminska B. Molecular characterization of STAT signaling in inflammation and tumorigenesis. In: Kozlov SV, editor. Inflammation and cancer: methods and protocols. volume 2, molecular analysis and pathways. New York: Humana Press, 2009. p. 265-78. (Methods in Molecular Biology, 512) ISBN 978-1-60327-529-3. GLIOMA; TRANSDUTOR DE SINAL E ACTIVADOR DA TRANSCRICAO; QUINASES JANUS; FOSFORILACAO STAT; STAT EXPRESSAO GENICA DEPENDENTE; OLIGODESOXINUCLEOTIDO STAT CHAMARIZ |
| 8/46 | US=49-F / Câncer Jiang BH,Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis. In: Woude GFV, Klein G. Advances in cancer research. Amsterdam: Elsevier, 2009. p. 19-65. ISBN 978-0-12-3744371. PI3K/PTEN; SINALIZACAO NA ANGIOGENESE; SINALIZACAO TUMORIGENESE; ANGIOGENESE REGULADA POR VEGF; ABERRACOES GENETICAS DE PI3K, PTEN E AKT EM CANCER; PAPEIS DE PI3K E AKT NA REGULACAO DA ANGIOGENESE; CRESCIMENTO DO TUMOR; METASTASE DE TUMOR; ANGIOGENESE TUMORAL |
| 9/46 | US=18 / Gastro Gallmeier E, Kern SE. Genetic pathways in pancreatic tumorigenesis. In: Beger HG, Matsuno S, Cameron JL. Diseases of the pancreas: current surgical therapy. New York: Springer, 2008. p. 513-26. ISBN 978-3-540-28655-4. TUMORIGENESE DE PANCREAS; TUMORIGENESE; CANCER DE PANCREAS; ONCOGENES; GENES SUPRESSORES DE TUMORES; GENOMA DE MANUTENCAO DE GENES |
| 10/46 | US=84-A / Biol/Mol Wolfrain LA, Letterio JJ. Transformig growth factor-B in developing and advanced cancers: perturbations of TGF-B signaling in leukocytes as drivers of leukemogenesis and epithelial tumorigenesis. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 181-202. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0. FATOR TRANSFORMADOR DE CRESCIMENTO - B; TGF-B; SMAD; LEUCEMOGENESE; CELULAS T; IMUNOTERAPIA TUMOR; MODELOS DE RATO; ESTROMA; LINFOCITOS EPITELIAIS INTERACCOES |
| 11/46 | US=84-A / Biol/Mol Suzuki E, Albelda SM. Development of inhibitors of transforming growth factor-B signaling for therapy: soluble type II transforming growth factor-B receptor inhibits tumorigenesis by augmenting host ntitumor immunity. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 697-706. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0. TGF-B; IMUNIDADE ANTITUMORAL; MESOTELIOMA MALIGNO; SOLUVEL DO TIPO II DO RECEPTOR DE TGF-B |
| 12/46 | US=86 / Biol/Mol Fan Y, Dutta J, Gupta N, Fan G, Gélinas C. Regulation of programmed cell death by NF-kB and its role in tumorigenesis and therapy. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 223-50. (Advances in Experimental Medicina and Biology, 615) ISBN 978-1-4020-6553-8. REGULACAO DA MORTE CELULAR; NF-KB; TUMORIGENESE; TERAPIA; APOPTOSE; NECROSE; FATOR DE TRANSCRICAO; CANCER |
| 13/46 | US=90 / Biol/Mol Normanno N, Bianco C, De Luca A, Strizzi L, Gallo M, Mancino M, Salomon DS. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: expression and prognostic significance of the EGFR in solid tumors. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 221-34. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. EGFR; ERBB2; ERBB3; ERBB4; EGF-COMO FATOR DE CRESCIMENTO; CANCER; PROGNOSTICO |
| 14/46 | US=90 / Biol/Mol Bennett HL, Brummer T, Timpson P, Patterson KI, Daly RJ. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: signaling by the EGF receptor in human cancers: accentuate the positive, eliminate the negative. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 235-55. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. SRC; RAS; RAF; ERK; PI3-QUINASE; PTEN; EGFR INIBIDORES; LOOPS DE FEEDBACK; C-CBL; ENDOCITOSE |
| 15/46 | US=90 / Biol/Mol Box C, Peak J, Rogers S, Eccles S. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: EGFR signaling in invasion, angiogenesis and metastasis. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 257-76. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. INVASAO; ADESAO; MOTILIDADE; PROTEOLISE; ANGIOGENESE; LINFANGIOGENESE; METASTASE |
| 16/46 | US=90 / Biol/Mol Wikstrand CJ, Bigner DD. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: constitutive activation of truncated EGF receptors in glioblastoma. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 277-92. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. AMPLIFICACAO DO GENE; IMUNOTERAPIA; MUTACAO; NEOPLASIAS DO SISTEMA NERVOSO; TRANSDUCAO DE SINAL |
| 17/46 | US=90 / Biol/Mol Eberhard DA. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: EGFR mutations, other molecular alterations related to sensitivity to EGFR-targeted therapies in non-small cell lung cancer. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 293-336. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; INIBIDORES DE QUINASE DE TIROSINA; DIAGNOSTICOS MOLECULARES; MUTACOES; HIBRIDACAO IN SITU FLUORESCENTE; IMUNOHISTOQUIMICA; CANCER DE PULMAO |
| 18/46 | US=90 / Biol/Mol Dannenberg AJ, Subbaramaiah K. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: crosstalk between COX-2 and EGFR: apontential therapeutic opportunity. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 337-51. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. CICLOOXIGENASE-2; PROSTAGLANDINAS; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; CROSSTALK; CANCER |
| 19/46 | US=90 / Biol/Mol Thomson S, Haley JD, Yauch R. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: cellular sensitivity to EGF receptor inhibitors. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 353-68. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. EGFR; HER2; HER3; ERLOTINIB; A TRANSICAO EPITELIAL MESENQUIMAL; INIBIDORES DE QUINASE DE TIROSINA |
| 20/46 | US=90 / Biol/Mol Buck E, Eyzaguirre A, Iwata KK. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: utilizing combination of molecular targeted agents to sensitize tumor cells to EGFR inhibitors. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 369-82. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. EMT; TRANSICAO EPITELIAL MESENQUIMAL; ERLOTINIB; EGFR; IGF-1R; ER; HER3; MTOR; HDAC; SRC; COX-2 |